Vaccine News and Research

Latest Vaccine News and Research

UQ and Moderna partner to research and develop vaccines against global public health threats

The University of Queensland has been selected as one of the first launch institutions in the world to partner with biotechnology company Moderna to research and develop vaccines to tackle the world's greatest global public health threats.

9 Mar 2022

Clinical trial of novel rabies vaccine in human volunteers begins in Tanzania

The University of Oxford and the Ifakara Health Institute today announced the vaccination of the first participants in a Phase Ib/II trial testing a novel rabies vaccine in human volunteers in Tanzania.

9 Mar 2022

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Researchers assessed the levels of neutralizing antibodies in coronavirus disease patients.

9 Mar 2022

Rates of rapid antigen test positivity after day 5 from a positive COVID-19 test

A recent study evaluated the positivity rates of COVID-19 rapid antigen tests in infected individuals.

9 Mar 2022

Viral load reduction effectiveness of SARS-CoV-2 BNT162b2 mRNA booster vaccine wanes with time

In a new study, researchers conducted a retrospective analysis of the SAR-CoV-2 reverse transcriptase - quantitative polymerase chain reaction test measurements.

9 Mar 2022

Rabies transmission via vampire bats identified in Brazil

In a new study, researchers evaluated the concerns regarding the hematophagous bat-borne rabies in Brazil.

9 Mar 2022

The CDC’s new guidelines on covid risk and masking elicit mixed feelings

When the Centers for Disease Control and Prevention last month unveiled updated covid-19 guidelines that relaxed masking recommendations, some people no doubt sighed in relief and thought it was about time.

9 Mar 2022

Lower exosome component 2 expression protects against clinical SARS-CoV-2 infection

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that the lower expression of EXOSC2 human protein safeguards from clinical coronavirus disease 2019 (COVID-19). This protective effect was via the reduced EXOSC2 expression-associated suppression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication.

9 Mar 2022

Study suggests recent common cold may actually lead to worse COVID-19 disease

A new study published in the Journal of Infectious Diseases shines an unexpected light on the notion that pre-existing immunity to common cold coronaviruses can protect us from coronavirus disease 2019 (COVID-19) – and reveals that this may actually put certain individuals at risk of more severe clinical presentations.

8 Mar 2022

Three new drug companies join the COVIDRIVE consortium to study vaccine effectiveness

Three new drug companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium, becoming partners of this project coordinated by the Vaccine Research Department of the Foundation for the Promotion of Health and Biomedical Research of Valencia Region (Fisabio), an affiliate of the Conselleria de Sanitat Universal i Salut Pública, along with the company specialized in pharmacovigilance and epidemiology, P95.

8 Mar 2022

Biotech spinout receives $42 million to develop 'future-proofed' coronavirus vaccines

Prime Minister Boris Johnson today announced that DIOSynVax, a biotech spinout of the University of Cambridge, will receive $42million to develop a vaccine candidate that could provide protection against both existing and future variants of SARS-CoV-2 - the virus that causes COVID-19 - as well as other major coronaviruses, including those that cause SARS and MERS.

8 Mar 2022

Study evaluates heterologous vaccination scheme in children using two SARS-CoV-2 RBD protein vaccines

A recent study predicted the efficacy of the SOBERANA 02 and SOBERANA Plus COVID-19 vaccines in children.

8 Mar 2022

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Researchers developed a vaccine candidate termed Ad26.COV2.S.529, encoding a stabilized Omicron-based S protein resembling ancestral SARS-CoV-2 Wuhan-Hu-1 S protein.

8 Mar 2022

Thermostable next-generation vaccine candidate against SARS-CoV-2 variants of concern studied in mice

Researchers developed a highly thermo-tolerant vaccine candidate that elicited high nAb titers in mice against several SARS-CoV-2 variants of concerns.

8 Mar 2022

Current and future perspectives of mRNA technology

New research reports on the current and future perspectives on messenger ribonucleic acid technology, the platform on which the first successful COVID-19 vaccine was based.

8 Mar 2022

Effect of COVID-19 mRNA vaccine on in vitro glial cells of the brain studied by Raman spectroscopy and imaging

Researchers studied how the mRNA-based BNT162b2 COVID-19 vaccine altered the biochemical composition of glial and glioma brain cells in vitro.

8 Mar 2022

Comparative immunogenicity of reduced and standard BNT162b2 and mRNA-1273 boosters in CoronaVac vaccinees

Researchers compared the immunogenicity of the reduced and standard doses of the BNT162b2 and mRNA-1273 vaccine in adults immunized with two doses of the CoronaVac vaccine.

8 Mar 2022

Study finds Omicron BA.2 responsible for more but less infectious breakthrough infections

In a recent study posted to the medRxiv* pre-print server, researchers evaluated the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) infections between December 23, 2021, and February 20, 2022, in Qatar to understand how Omicron subvariants, vaccination, and prior infection status impacted these cases.

8 Mar 2022

Development of RT-qPCR assays for differentiating SARS-CoV-2 Omicron BA.1 and BA.2 variants

In a recent study posted to the medRxiv*preprint server, a team of researchers from Israel developed and validated novel reverse transcriptase - quantitative polymerase chain reaction (RT-qPCR) assays. The new assays enable the rapid and high throughput identification and differentiation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 and BA.2 variants.

8 Mar 2022

Higher SARS-CoV-2 load in morning-collected samples

In a recent study posted to the medRxiv* preprint server, researchers identified that morning-collected nasal and saliva samples yielded better detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially in tests with low to moderate analytical sensitivity.

8 Mar 2022

Vaccine News and Research

Latest Vaccine News and Research

UQ and Moderna partner to research and develop vaccines against global public health threats

Clinical trial of novel rabies vaccine in human volunteers begins in Tanzania

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Rates of rapid antigen test positivity after day 5 from a positive COVID-19 test

Viral load reduction effectiveness of SARS-CoV-2 BNT162b2 mRNA booster vaccine wanes with time

Rabies transmission via vampire bats identified in Brazil

The CDC’s new guidelines on covid risk and masking elicit mixed feelings

Lower exosome component 2 expression protects against clinical SARS-CoV-2 infection

Study suggests recent common cold may actually lead to worse COVID-19 disease

Three new drug companies join the COVIDRIVE consortium to study vaccine effectiveness

Biotech spinout receives $42 million to develop 'future-proofed' coronavirus vaccines

Study evaluates heterologous vaccination scheme in children using two SARS-CoV-2 RBD protein vaccines

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Thermostable next-generation vaccine candidate against SARS-CoV-2 variants of concern studied in mice

Current and future perspectives of mRNA technology

Effect of COVID-19 mRNA vaccine on in vitro glial cells of the brain studied by Raman spectroscopy and imaging

Comparative immunogenicity of reduced and standard BNT162b2 and mRNA-1273 boosters in CoronaVac vaccinees

Study finds Omicron BA.2 responsible for more but less infectious breakthrough infections

Development of RT-qPCR assays for differentiating SARS-CoV-2 Omicron BA.1 and BA.2 variants

Higher SARS-CoV-2 load in morning-collected samples

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in